A 74-year-old woman develops haemolytic anaemia and stress cardiomyopathy after a tick bite, highlighting a rare cardiac ...

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...